The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/300 - 1/1000. Detects a band of approximately 59 kDa (predicted molecular weight: 59 kDa).
Use at an assay dependent concentration.
FunctionInvolved in the activation cascade of caspases responsible for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner. May participate in the granzyme B apoptotic pathways. Cleaves and activates caspase-3, -4, -6, -7, -8, and -9. Hydrolyzes the small- molecule substrates, Tyr-Val-Ala-Asp- -AMC and Asp-Glu-Val-Asp- -AMC. Isoform C is proteolytically inactive.
Tissue specificityDetectable in most tissues. Lowest expression is seen in brain, kidney, prostate, testis and colon.
Involvement in diseaseDefects in CASP10 are the cause of autoimmune lymphoproliferative syndrome type 2A (ALPS2A) [MIM:603909]. ALPS2 is characterized by abnormal lymphocyte and dendritic cell homeostasis and immune regulatory defects. Defects in CASP10 are a cause of familial non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. Defects in CASP10 are a cause of gastric cancer (GASC) [MIM:613659]. A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
Sequence similaritiesBelongs to the peptidase C14A family. Contains 2 DED (death effector) domains.
Post-translational modificationsCleavage by granzyme B and autocatalytic activity generate the two active subunits. Phosphorylated upon DNA damage, probably by ATM or ATR.
Caspase 10 apoptosis related cysteine peptidase antibody
Caspase-10 subunit p12 antibody
FADD like ICE2 antibody
Fas associated death domain protein antibody
FAS-associated death domain protein interleukin-1B-converting enzyme 2 antibody
FLICE 2 antibody
ICE like apoptotic protease 4 antibody
ICE-like apoptotic protease 4 antibody
Interleukin 1B converting enzyme 2 antibody
MCH 4 antibody
Anti-Caspase-10 antibody images
Western blot - Anti-Caspase-10 antibody (ab52225)
All lanes : Anti-Caspase-10 antibody (ab52225) at 1/300 dilution
Lane 1 : extracts from HeLa cells, Lane 2 : extracts from HeLa cells, with immunizing peptide
Predicted band size : 59 kDa Observed band size : 59 kDa
Anti-Caspase-10 antibody (ab52225)
Immunohistochemical analysis of Caspase-10 expression in paraffin embedded human lung carcinoma tissue, using ab52225 at a dilution of 1:50. Left: untreated sample. Right: sample treated with immunising peptide.
Immunohistochemical analysis of Caspase 10 expression in paraffin embedded human lung carcinoma tissue, using ab52225 at a dilution of 1/50.
Left: untreated sample. Right: sample treated with immunising peptide.
References for Anti-Caspase-10 antibody (ab52225)
has not yet been referenced specifically in any publications.
Publishing research using ab52225? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"